Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Ascendis Pharma A/S publishes a filing, an earnings call transcript or a press release.

Get ASND alerts

About Jan Mikkelsen

Jan Mikkelsen is recorded as CEO at Ascendis Pharma A/S (ASND). Jan Mikkelsen has spoken on 21 earnings calls and 1 other investor event across 1 company, most recently for Ascendis Pharma A/S on September 15, 2026. Ascendis Pharma A/S is classified in the Biotechnology industry within the Healthcare sector.

Jan Mikkelsen on recent calls

“That is an open question where I can come up with a lot of answers because a lot of things is happening at Ascendis. First of all, we also had a Presco lease yesterday related to buying back shares for 400 million US dollars.”
CEO, Morgan Stanley 24th Annual Global Healthcare Conference ·
“During the second quarter, achievement of important milestones and strong demand for our Transcom products continue to drive the transformation of the incentives into a leading global biopharma company.”
CEO, Q2 2026 Ascendis Pharma Earnings Conference Call ·
“The first quarter of 2026 was an inflection point for Ascendis, with the FDA approval of our third TransCon product, YUVIWEL. Our revenues are growing rapidly. We are profitable.”
CEO, Ascendis Pharma A/S Q1 FY2026 Earnings Call ·
“In the first quarter of 2025, Ascendis continued the strong start of our local YORVIPATH launch as well as key development and regulatory progress supporting our long-term growth strategy to be a leading biopharma company.”
CEO, Ascendis Pharma A/S Q1 FY2025 Earnings Call ·
“2024 was a pivotal year for Ascendis as we achieved key milestones that set us up to deliver strong growth and value creation in 2024 and beyond.”
CEO, Ascendis Pharma A/S Q4 FY2024 Earnings Call ·

Affiliation history

Company network

Recent activity

Show 10 earlier activities